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Abstract
Background: Although several studies indicate a link between vitamin D status and blood pressure (BP), the
results are inconsistent. The purpose of this study is to investigate whether in predominantly non-obese elderly
people without vitamin D deficiency or very high intact parathyroid hormone (iPTH) levels serum 25-
hydroxyvitamin D3 [25(OH)D3] and iPTH are independently associated with BP.
Methods: Cross-sectional data of 132 non-institutionalised subjects (90 women and 42 men, aged 66- 96 years)
from Giessen, Germany, were analysed. Serum 25(OH)D3 and iPTH were measured by an electrochemiluminescence
immunoassay and BP was determined with a sphygmomanometer. We performed univariate and multiple
regression analyses to examine the influence of 25(OH)D3 and iPTH on BP with adjustments for age, body
composition and lifestyle factors.
Results: While iPTH had no impact on BP, 25(OH)D3 was negatively associated with systolic BP in men, but not in
women. After splitting the cohort into antihypertensive medication users and non-users, 25(OH)D3 was a significant
predictor for systolic and diastolic BP only in men not receiving antihypertensive medicine, even after multiple
adjustment. Adjustment for 25(OH)D3 resulted in an inverse association of iPTH with diastolic BP also only in men
without intake of antihypertensive medicine.
Conclusions: In elderly men without vitamin D deficiency and not taking antihypertensive medicine, 25(OH)D3
may be a negative determinant of BP, independent of iPTH, body composition and lifestyle factors. Furthermore,
iPTH may be an independent negative determinant of diastolic BP in men not taking antihypertensive medicine.
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Background
Vitamin D may play an important role in blood pressure
(BP) regulation. Numerous cells within the human body
are able to express the vitamin D receptor, including car-
diomyocytes, vascular smooth muscle cells, endothelial
cells and renin-producing juxtaglomerular cells [1-3].
At present, results regarding the impact of vitamin D
status, determined by circulating 25-hydroxyvitamin D
concentrations [25(OH)D], on BP or hypertension are
inconsistent. While some studies reported a negative asso-
ciation between vitamin D and BP [4-11], other studies
failed to confirm a relationship [12-18] or even reported a
positive association [19]. Parathyroid hormone (PTH),
which rises in case of a low vitamin D status, may also
affect BP [17,18,20-22], but studies are also inconsistent.
Subjects in previous studies were partially hypertensive
patients [16], morbidly obese [12] or suffered from vitamin
D deficiency [23] or primary hyperparathyroidism [22].
Some of the previous studies reported non-fasting mea-
surements [13,17,20], focused on either women or men
[5,18] or did not control for potential confounders, such
as age, estimated glomerular filtration rate (eGFR), body
composition, nutrient intake, use of vitamin D supple-
ments, antihypertensive medication, sun exposure, physi-
cal activity or smoking [4,13,22], which may be associated
with vitamin D status, PTH and BP. In addition, previous
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PTH without considering the interaction between both
[6-10].
Elderly people are at risk of developing hypertension
[24] and of suffering from vitamin D deficiency because
of age-related declines in endogenous vitamin D synth-
esis, sun exposure and dietary intake [25]. Therefore, and
in view of the inconsistent results of previous studies, the
primary objective of our study was to test whether 25-
hydroxyvitamin D3 [25(OH)D3] or intact PTH (iPTH)
contribute to BP in non-institutionalised elderly people,
independently of each other and potential confounding
factors, such as age, eGFR, body composition, sun expo-
sure, physical activity, vitamin D and calcium intake,
alcohol consumption and smoking behaviour. Further-
more, we analysed whether differences regarding the
impact of 25(OH)D3 and iPTH on BP exist between sub-
jects receiving antihypertensive drugs and subjects with-
out such a medication.
Methods
Subjects
Subjects were participants of the GISELA study, a pro-
spective cohort study in which the nutrition and health
status of senior citizens from Giessen, Germany (50°35’
North) have been observed at annual intervals since
1994 and biannual intervals since 1998. For enrolment,
subjects had to be at least 60 years of age and physically
mobile. All investigations took place in the Institute of
Nutritional Science in Giessen from July to October.
After subjects had become familiar with the trial proce-
dure, written informed consent was obtained from each
participant. The study protocol was approved by the
Ethical Committee of the Faculty of Medicine at the Jus-
tus-Liebig-University, Giessen.
The present investigation reports cross-sectional data
from the GISELA study obtained in 2008. Subjects with
incomplete data were excluded (n = 118), as were indivi-
duals who suffered from chronic kidney disease (n =4 )
or oedema (n = 6) or who took diuretics (n =8 ) .S e v e n
subjects were identified as outliers regarding their 25
(OH)D3 and iPTH measurements and/or the residuals
of the regression analyses and were therefore not
included. After these exclusions, of the 275 elderly peo-
ple who took part in the follow-up in 2008, data from
90 women and 42 men remained for the following
analysis.
Anthropometric data and body composition
Body weight, body height, body mass index (BMI), waist-
to-hip ratio (WHR), waist circumference (WC) and hip
circumference were determined as described elsewhere
[26]. Body composition was recorded by a single-fre-
quency (50 kHz) bioelectrical impedance analyser (Akern-
RJL BIA 101/S, Data Input, Frankfurt, Germany) according
to the instructions of the manufacturer and the predictive
formula from Roubenoff et al. [27]. This equation was
chosen because it was derived from a reference population
similar in age to our study subjects and with the same
measurement conditions. Moreover, this equation has
been validated against dual-energy X-ray absorptiometry
(DXA) body composition measurements.
Lifestyle factors
Nutritional intake was determined using a three-day esti-
mated dietary record, which was developed and validated
for the GISELA study [28]. Smoking behaviour, time
spent outdoors as indicator for sun exposure, physical
activity patterns and further data, such as age, diseases,
medications and supplement intake, were collected using
self-administered questionnaires. Smoking behaviour was
coded as a dummy variable in two categories: never-smo-
kers were allocated to category one, while category two
comprised both current smokers and ex-smokers. The
use of antihypertensive drugs and the intake of vitamin D
supplements were also coded as dummy variables (no/
yes). The physical activity level (PAL) of each participant
was assessed as described elsewhere [26].
Blood pressure
Arterial BP was measured between 7:00 a.m. and 11:00
a.m. after a rest of at least 5 min via a sphygmoman-
ometer with a cuff and a stethoscope to detect the Kor-
otkoff sound. Each subject was asked to take a seated
position, and their arm was supported at heart level.
The first Korotkoff sound was defined as systolic BP
(SBP), while the last sound was determined as diastolic
BP (DBP). Hypertension was defined as SBP > 140
mmHg and/or DBP > 90 mmHg and/or intake of anti-
hypertensive drugs [29].
Laboratory measurements
Blood samples were collected between 7:00 a.m. and
11:00 a.m. after an overnight fast. After immediate centri-
fugation, serum aliquots were stored at -70°C for further
analysis. Both 25(OH)D3 and iPTH were measured by an
electrochemiluminescence immunoassay (ECLIA, Modu-
lar E170, Roche Diagnostics
®, Mannheim, Germany) in
the Limbach Laboratory, Heidelberg, Germany. The coef-
ficient of variation for the total analytic precision of this
assay was ≤ 9.9 % for 25(OH)D3 and ≤ 5.9 % for iPTH.
The lower detection limits of this assay were 10.0 nmol/L
for 25(OH)D3 and 0.127 pmol/L for iPTH. More details
are available from Roche Diagnostics [30,31].
We defined 25(OH)D3 levels < 25.0 nmol/L as vitamin
D-deficient. Due to the lack of an international consen-
sus on an optimal 25(OH)D3 status, we applied two cut-
o f fv a l u e sa sa d e q u a t e( ≥ 50 nmol/L and ≥ 75 nmol/L).
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tion (Shimadzu UV-160A) according to the Jaffé reac-
tion [32]. The eGFR, which served as a marker of the
kidney function, was calculated with the simplified Mod-
ification of Diet in Renal Disease study (MDRD) for-
mula: eGFR (mL/min/1.73 m
2) = 186 × (serum
creatinine mg/dL)
-1.154 ×a g e
-0.203 × (0.742 if female)
[33].
Statistical analysis
The characteristics of the study participants were
expressed as median and 5
th to 95
th percentile due to non-
normally distributed data. Depending on the sample size,
normal distribution was tested by the Shapiro-Wilk test
and by the Kolmogorov-Smirnov test with the Lilliefors
correction and by visual inspection of histograms. Descrip-
tive characteristics were compared between sexes via the
Mann-Whitney U test for continuous variables. The c
2
test or, alternatively, Fisher’s exact test was used for cate-
gorical variables. The cohort was split by BP into two
groups such that normotensive subjects were compared
with hypertensive participants regarding the prevalence of
vitamin D insufficiency by means of the Fisher’s exact test.
In addition, subjects under antihypertensive medication
were compared to subjects free of antihypertensive treat-
ment regarding BP values, anthropometric data, % TBF,
25(OH)D3, iPTH as well as the prevalence of vitamin D
insufficiency using the Mann-Whitney U test and the Fish-
er’s exact test when appropriate.
We examined associations between 25(OH)D3 and
iPTH as well as associations of 25(OH)D3,i P T H ,e G F R ,
age, parameters of anthropometry and body composition,
and lifestyle factors with BP by univariate regression ana-
lyses. Those variables that exhibited a significant associa-
tion with either SBP or DBP in univariate analyses were
considered as confounding variables in the sex-specific
multiple regression analyses with SBP and DBP as depen-
dent variables and 25(OH)D3 and iPTH as independent
variables, respectively. In addition, we conducted a sub-
group analysis by comparing participants taking antihy-
pertensive medicine with subjects without such a
treatment. Because there were no major changes in the
results when 25(OH)D3 and iPTH were logarithmically
transformed, we report only the non-transformed data.
All statistical analyses were conducted with SPSS 18.0 for
Windows (SPSS Inc., Chicago, USA). The significance
level was set at P < 0.05. All tests were two-tailed.
Results
Characteristics of the study subjects
The characteristics of the study population are sum-
marised in Table 1. No significant differences between
sexes were observed in BP, 25(OH)D3,i P T H ,a g e ,B M I ,
PAL, sun exposure, vitamin D and calcium intake and
in the percentage of subjects who received antihyperten-
sive drugs or who suffered from elevated BP. Men had
higher values for WC, WHR, eGFR and alcohol con-
sumption and included a lower percentage of never-
smokers than women, whereas women had a higher %
TBF. The median vitamin D intake of both women and
men did not meet the current recommendation of 20 μg
vitamin D per day [34].
None of the subjects had a serious vitamin D deficiency
(25(OH)D3 < 25 nmol/L). However, 23.3 % (n =2 1 )o f
the women and 21.4 % (n = 9) of the men had 25(OH)D3
levels < 50 nmol/L, while 16.7 % (n = 15) of the female
and 21.4 % (n = 9) of the male participants had a 25(OH)
D3 status of ≥ 75 nmol/L. Hyperparathyroidism, which
was defined as iPTH levels > 6.9 pmol/L, had 6.7 % (n =
6) of the women and 9.5 % (n = 4) of the men. In the uni-
variate regression analysis using 25(OH)D3 as the inde-
pendent and iPTH as the dependent variable, an inverse
association was observed only in women (women: b =
-0.297; P = 0.004 and men: b = -0.150; P = 0.342).
In women, SBP, DBP, anthropometric data (except for
WHR) and % TBF were significantly higher in subjects
under antihypertensive medication compared to women
free of antihypertensive treatment (all P < 0.01), whereas
men showed no such differences based on antihyperten-
sive treatment (all P > 0.05). Neither 25(OH)D3 nor
iPTH were significantly different between BP medication
users and non-users in either sex (all P > 0.200).
Prevalence of vitamin D insufficiency and blood pressure
Hypertension had 70.0 % of the women and 71.4 % of the
men. The prevalence of vitamin D insufficiency did not
differ between hypertensive and normotensive subjects,
independent of using the 50 nmol/L (women: 23.8 % vs.
22.2 %, P = 1.000 and men: 26.7 % vs. 8.3 %, P = 0.247)
or 75 nmol/L (women: 79.4 % vs. 92.6 %, P =0 . 2 1 5a n d
men: 86.7 % vs. 58.3 %, P = 0.090) cut-off value to define
an optimal vitamin D status. In addition, no differences
between participants who were under antihypertensive
medication and participants without antihypertensive
treatment were found with respect to the prevalence of
vitamin D insufficiency, independent of using the 50
nmol/L (women: 23.6 % vs. 22.9 %, P = 1.000 and men:
20.8 % vs. 22.2 %, P = 1.000) or 75 nmol/L (women: 78.2
%v s .9 1 . 4% ,P = 0.147 and men: 83.3 % vs. 72.2 %, P =
0.462) cut-off value.
Univariate and multiple regression analyses regarding the
association between vitamin D status, intact parathyroid
hormone and blood pressure
Table 2 presents the results of the univariate regression
analyses of SBP and DBP with relevant parameters. In
women, SBP was positively associated with BMI, WC, %
TBF and antihypertensive medication, whereas DBP was
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with antihypertensive treatment. In men, SBP was nega-
tively influenced by 25(OH)D3 and positively associated
with WHR, whereas DBP was inversely linked to cal-
cium intake and positively associated with WC and
WHR.
T h er e s u l t so ft h em u l t i p l er e g r e s s i o na n a l y s e sf o r
each sex are given in Table 3. Because of the observed
collinearity of WC, WHR, BMI and % TBF (data not
shown), the variable that showed the strongest associa-
tion with SBP or DBP (Table 2) was added as an inde-
pendent variable to the respective model. Consequently,
%T B Fw a si n c l u d e da sa ni n d e p e n d e n tv a r i a b l ei nt h e
female model, while WHR was integrated in the model
for men. After adjustment of BP for age, % TBF, antihy-
pertensive medication and mutual adjustment for iPTH
or 25(OH)D3, neither 25(OH)D3 nor iPTH predicted BP
in women. In men, even after adjusting BP for iPTH,
WHR and calcium intake, 25(OH)D3 remained an inde-
pendent negative predictor of SBP. Besides 25(OH)D3,
WHR was also a predictor of SBP, and together they
accounted for approximately 21.9 % of the variance of
SBP.
In men, but not in women, BP medication-users and
non-users differed regarding the association between 25
(OH)D3, iPTH and BP (Table 4): In men, significant
inverse associations between 25(OH)D3 and both SBP
and DBP were only present in the group free of antihy-
pertensive treatment. Serum iPTH had no impact on BP
until adjustment for 25(OH)D3 was performed, where-
upon a negative association between iPTH and DBP was
only found in subjects free of antihypertensive treat-
ment. The linear relationships of 25(OH)D3 with SBP
and DBP in men separated by the intake of antihyper-
tensive medicine are illustrated in Figure 1.
Discussion
This is the first investigation in a non-institutionalised
elderly German cohort without vitamin D deficiency
showing an independent association of 25(OH)D3 with
SBP in elderly men by considering a variety of potential
confounding factors including iPTH. Whether this asso-
ciation reflects a causal relationship is open to discussion
because of the cross-sectional character of our study. With
regard to the mechanism of how the vitamin D endocrine
system acts as a regulator of BP several theories are cur-
rently being discussed, including the inhibition of the
renin-angiotensin system and the enhancement of insulin
sensitivity by vitamin D as well as the direct impact of vita-
min D on vasculature and heart muscle [1,2,35]. In a
population-based study, a low 25(OH)D status has been
linked to increased heart rate and rate-pressure product,
such that an enhancement of cardiac work due to a subop-
timal vitamin D status can be assumed [10]. However, the
Table 1 Descriptive characteristics of the study population
Women (n = 90) Men (n = 42)
Median P5,P 95 Median P5,P 95 P
a)
Age (y) 75.5 68.0-86.5 76.0 70.0-84.7 0.321
Body mass index (kg/m
2) 26.9 21.1-34.5 26.3 22.9-32.3 0.456
Waist circumference (cm) 90.0 71.6-108.4 99.0 84.6-113.7 < 0.0001
Waist-to-hip ratio 0.85 0.75-0.93 0.95 0.86-1.06 < 0.0001
Total body fat (%) 42.4 32.6-50.2 28.9 21.6-37.9 < 0.0001
25(OH)D3 (nmol/L) 59.4 40.5-90.6 66.9 39.9-88.8 0.132
iPTH (pmol/L) 4.5 2.3-7.4 4.1 1.8-8.3 0.315
Systolic blood pressure (mmHg) 140.0 110.0-167.8 130.0 110.0-181.9 0.327
Diastolic blood pressure (mmHg) 72.0 60.0-90.0 70.0 60.0-92.4 0.172
eGFR (mL/min/1.73 m
2) 56.2 43.1-71.3 63.7 46.5-80.4 < 0.0001
Vitamin D intake (μg/d) 2.5 0.3-10.1 3.3 1.0-11.3 0.149
Calcium intake (g/d) 1.0 0.5-1.7 1.0 0.6-1.6 0.961
Alcohol intake (g/d) 2.3 0.0-16.1 5.5 0.0-30.0 0.013
Sun exposure (min/d) 120.0 40.0-360.0 150.0 23.8-394.0 0.071
Physical activity level 1.7 1.5-1.9 1.6 1.4-1.9 0.319
Current or ex-smokers, n (%) 21 23.3 30 71.4 < 0.0001
Vitamin D supplement users, n (%) 13 14.4 2 4.8 0.143
Elevated blood pressure, n (%)
b) 38 42.2 15 35.7 0.569
Antihypertensive drugs, n (%) 55 61.1 24 57.1 0.706
Abbreviations: P5, 5th percentile; P95, 95th percentile; 25(OH)D3, 25-hydroxyvitamin D3; iPTH, intact parathyroid hormone; eGFR, estimated glomerular filtration
rate.
a) Mann-Whitney U test for continuous variables and c
2 test for categorical variables.
b) Elevated blood pressure was defined as SBP > 140 mmHg and/or DBP > 90 mmHg.
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be mediated by PTH [17,20]. Primary hyperparathyroidism
has been linked to increased intima-media thickness of the
carotid artery as well as carotid stiffness [22]. Furthermore,
elevated BP could increase the urinary excretion of cal-
cium, thereby leading to lower serum calcium, which
consequently up-regulates PTH secretion [14]. In our
investigation, no associations were present between iPTH
and BP in the unstratified analysis independent of sex and
multiple adjustment, which is in accordance with some [5]
but not all previous studies [11,17,18,21]. There is evi-
dence that the association of iPTH with BP is more
Table 2 Univariate linear regression analyses between blood pressure and other parameters
a)
Women (n = 90) Men (n = 42)
SBP DBP SBP DBP
SBP (mmHg) - 0.516 **** - 0.698 ****
25-Hydroxyvitamin D3 (nmol/L) -0.068 -0.005 -0.388 * -0.235
Intact parathyroid hormone (pmol/L) -0.007 -0.087 0.101 0.088
eGFR (mL/min/1.73 m
2) -0.019 0.123 -0.139 0.060
Age (y) -0.026 -0.300 ** 0.099 0.088
Body mass index (kg/m
2) 0.276 ** 0.154 0.229 0.211
Waist circumference (cm) 0.230 * 0.090 0.282 0.342 *
Waist-to-hip ratio 0.167 0.019 0.411 ** 0.423 **
Total body fat (%) 0.382 *** 0.194 0.012 0.071
Vitamin D intake (μg/d) -0.019 -0.169 0.082 -0.024
Calcium intake (mg/d) -0.086 -0.027 -0.105 -0.365 *
Alcohol intake (g/d) -0.059 0.112 -0.039 0.158
Sun exposure (min/d) -0.032 -0.078 0.021 -0.066
Physical activity level -0.158 -0.194 -0.068 -0.095
Current or past smoking
b) -0.103 -0.116 0.136 -0.007
Antihypertensive medication
b) 0.332** 0.281** 0.230 0.131
Vitamin D supplement use
b) -0.031 0.041 0.010 0.098
Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate.
a) Univariate regression analyses with SBP and DBP as dependent variables. The shown values represent the standardised coefficient b.*P < 0.05; ** P < 0.01; ***
P < 0.001; ****P < 0.0001.
b) Dummy variable (no/yes).
Table 3 Multiple regression analyses using inclusion procedure of factors possibly associated with blood pressure
a)
Women (n = 90) SBP (mmHg) DBP (mmHg)
B b P B b P
Intercept 93.689 0.013 116.202 < 0.0001
25(OH)D3 (nmol/L) -0.059 -0.046 0.669 -0.067 -0.104 0.334
iPTH (pmol/L) -0.204 -0.017 0.871 -0.455 -0.075 0.468
Age (y) 0.010 0.003 0.976 -0.532 -0.327 0.002
BP medication 8.240 0.225 0.042 5.365 0.294 0.009
TBF (%) 1.029 0.292 0.011 0.033 0.019 0.866
Corr. R
2 0.141 0.143
Men (n = 42) SBP (mmHg) DBP (mmHg)
B b P B b P
Intercept 62.674 0.186 43.040 0.044
25(OH)D3 (nmol/L) -0.503 -0.356 0.015 -0.125 -0.198 0.160
iPTH (pmol/L) -0.725 -0.068 0.653 -0.049 -0.010 0.945
WHR 117.728 0.387 0.013 49.992 0.366 0.017
Calcium (mg/d) -0.003 -0.050 0.729 -0.010 -0.320 0.028
Corr. R
2 0.219 0.243
Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure; 25(OH)D3, 25-hydroxyvitamin D3; iPTH, intact parathyroid hormone; BP medication,
antihypertensive medication as dummy variable (no/yes); TBF, total body fat; WHR, waist-to-hip ratio.
a) Multiple linear regression analyses with SBP or DBP as
dependent variables. The results of the linear regression analyses are expressed in terms of B (the unstandardised coefficient), b (the standardised coefficient),
and the adjusted coefficient of determination (corr. R
2).
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medication users and non-users
a)
Women (n = 90) BP medication users (n = 55) BP medication non-users (n = 35)
SBP (mmHg) DBP (mmHg) SBP (mmHg) DBP (mmHg)
25(OH)D3 (nmol/L) Model 1 -0.119 -0.122 -0.069 0.201
Model 2 -0.085 -0.146 0.077 0.133
Model 3 -0.103 -0.164 0.197 0.158
iPTH (pmol/L) Model 1 -0.062 -0.088 0.202 -0.004
Model 2 -0.077 -0.066 0.132 -0.022
Model 3 -0.096 -0.097 0.215 0.045
Men (n = 42) BP medication users (n = 24) BP medication non-users (n = 18)
SBP (mmHg) DBP (mmHg) SBP (mmHg) DBP (mmHg)
25(OH)D3 (nmol/L) Model 1 -0.163 -0.015 -0.674 ** -0.579 *
Model 2 -0.207 -0.088 -0.619 * -0.529 *
Model 3 -0.207 -0.088 -0.843 ** -0.785 **
iPTH (pmol/L) Model 1 0.127 0.185 0.010 -0.194
Model 2 -0.015 0.054 -0.053 -0.144
Model 3 -0.016 0.053 -0.449 -0.512 *
Abbreviations: BP medication, antihypertensive medication; SBP, systolic blood pressure; DBP, diastolic blood pressure; 25(OH)D3, 25-hydroxyvitamin D3; iPTH,
intact parathyroid hormone.
a) Multiple linear regression analyses with SBP and DBP as dependent variables and 25(OH)D3 and iPTH as independent variables after splitting the cohort into
antihypertensive medication users and non-users, respectively. The results are expressed in terms of the standardised coefficient b. Model 1: unadjusted
association. Model 2: model 1 additionally adjusted for waist-to-hip ratio and calcium intake (mg/d) in men and age (y) and total body fat (%) in women. Model
3: model 2 plus mutual adjustment for iPTH (pmol/L) and 25(OH)D3 (nmol/L) in both the male and female model, respectively. * P < 0.05; ** P < 0.01.
Figure 1 Associations of 25-hydroxyvitamin D3 with blood pressure in men separated by the use of antihypertensive medicine.A )
Association between 25-hydroxyvitamin D3 and systolic blood pressure in men without medication. B) Association between 25-hydroxyvitamin
D3 and systolic blood pressure in men with medication. C) Association between 25-hydroxyvitamin D3 and diastolic blood pressure in men
without medication. D) Association between 25-hydroxyvitamin D3 and diastolic blood pressure in men with medication. The P values and the
standardised coefficients b were calculated by univariate regression analyses.
Jungert et al. Nutrition & Metabolism 2012, 9:20
http://www.nutritionandmetabolism.com/content/9/1/20
Page 6 of 9pronounced in subjects with elevated iPTH and/or sub-
jects with low calcium intake [13]. As the median calcium
intake of our cohort met the current recommendations of
1 g per day [36] and subjects with extreme iPTH values
were excluded, this may explain why we did not observe
an association between iPTH and BP.
We found an inverse association between 25(OH)D3
and iPTH in females, but not in males, which may be
attributed to hormonal differences, the lower sample
size of men and/or the higher % TBF in women. The
latter may result in a higher sequestration of 25(OH)D3
in the adipose tissue, which consequently up-regulates
iPTH secretion. The inverse association between 25
(OH)D3 and iPTH supports the requirement of a mutual
adjustment to evaluate independent effects of vitamin D
and iPTH on BP. Some studies have addressed the effect
of both 25(OH)D and PTH on BP in an elderly cohort
[4,17,18]; however, the majority of these studies per-
formed no mutual adjustment for 25(OH)D and PTH.
In two studies, 25(OH)D was not significantly associated
with BP, while elevated PTH was significantly related to
higher BP [17,18]. The authors argued that the reason
for the missing association of 25(OH)D with BP is per-
haps attributed to the high vitamin D status of their
participants [17,18]. It should be noticed that the med-
ian vitamin D status of our subjects was also well in the
range considered as sufficient. As in our study, Almirall
et al. [4] found an association of 25(OH)D with SBP,
but not with DBP, after adjustment for several covari-
ates; however this study included predominantly vitamin
D-insufficient [25(OH)D < 50 nmol/L] individuals and
did not control for PAL, sun exposure, vitamin D intake
and iPTH.
There are some studies in younger study populations,
which mutually adjusted for 25(OH)D and PTH. Jorde
et al. [37] reported a significant inverse cross-sectional
association of 25(OH)D quartiles with SBP in ≥ 25 year-
old subjects of the Tromsø Study, whereas the associa-
tion between 25(OH)D quartiles and DBP failed to
reach the significance level after multiple adjustment. In
agreement with our results, the additional inclusion of
PTH in the multiple regression models by Jorde et al.
[37] did not alter the results. In the NHANES 2003-
2006, both 25(OH)D and PTH were associated with BP
and the prevalence of hypertension in participants aged
≥ 20 years not taking antihypertensive medicine, but the
association of 25(OH)D with BP attenuated when
adjusted for PTH [11]. He and Scragg [20] reported a
non-significant association between 25(OH)D and BP in
subjects aged ≥ 20 years after controlling for both PTH
and BMI, while the relation of PTH with BP was not
considerably affected by 25(OH)D and BMI. Obesity is
considered as a risk factor for hypertension [38] and
may also be related to the vitamin D endocrine system
[39]. Therefore, body composition can be a confounding
factor in the associations between vitamin D, PTH and
BP [20,23]. In our male participants, body composition
as well as iPTH and lifestyle factors had no impact on
the association between 25(OH)D3 and SBP, which sug-
gests that the underlying mechanism in the association
between vitamin D and BP is independent of these con-
founding variables.
Our results support the hypothesis that the effect of
vitamin D on BP is more pronounced for SBP than for
DBP [9,37,40]. Interestingly, we found an independent
impact of 25(OH)D3 on SBP and DBP in the men with-
out antihypertensive treatment, but not in those under
antihypertensive medication. Moreover, iPTH was inver-
sely linked to DBP in men without antihypertensive
treatment after additional adjustment for 25(OH)D3,
which has not been reported before. In accordance with
our results, Scragg et al. [10] found no association
between 25(OH)D and SBP in a subgroup analysis with
participants taking BP lowering drugs, whereas in the
entire cohort a significant association was observed. In
contrast, others [17,18] found no significant association
between 25(OH)D and BP even after exclusion of sub-
jects using antihypertensive medication, whereas PTH
remained positively associated with BP. In one study,
the association between PTH and BP in elderly Chinese
men was stronger when subjects using antihypertensive
medication were excluded [18]. Almirall et al. [4]
reported a correlation of 25(OH)D with BP in subjects
with and without antihypertensive treatment; however,
this association was slightly stronger in the non-treated
group. The reason why the association between 25(OH)
D3 and BP as well as the relation between iPTH and
DBP was only present in the non-treated group of
elderly men in our study requires further investigation.
Although a false-positive finding cannot be ruled out,
one possible explanation could be that antihypertensive
medication includes often inhibitors of the renin-angio-
tensin system, so that vitamin D may have no additional
effect on BP in subjects taking antihypertensive drugs.
The unexpected negative impact of iPTH on DBP in
our study might be due to the enhanced production of
1,25-dihydroxyvitamin D3, which possibly functions as
an inhibitor of the renin-angiotensin system [1,2]. The
question arises why we did not obtain the same findings
in the women. The observed sex differences may be
attributed to hormonal differences and/or the fact that
significant differences in BP and % TBF between sub-
jects with and without antihypertensive medication were
only present in women. The higher BP in women under
antihypertensive medication may indicate that the anti-
hypertensive treatment so far was less efficient in the
female subjects. Because we have no information on the
brand, duration or dosage of antihypertensive drugs,
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related data may also be conceivable explanations. The
women might have taken other drugs than men, e.g.
beta blocker instead of inhibitors of the renin-angioten-
sin system. Finally, women and men differed substan-
tially with respect to their predictors of BP. Altogether,
these differences might explain why the 25(OH)D3 sta-
tus was only associated with BP in men.
In the present study, neither the estimated nutritional
vitamin D intake nor the assessed supplemental vitamin
D usage did affect BP, which is in accordance with the
literature [13,41,42]. The missing associations of vitamin
D intake with 25(OH)D3 and iPTH (data not shown)
and the low amount of vitamin D intake in our study
may be responsible for this observation. Instead, we
found that the calcium intake was an independent nega-
tive determinant of DBP in men, as noted in other stu-
dies [42]. One can assume that in case of an adequate
calcium intake and sufficient sun exposure, the habitual
vitamin D intake may have no additional effect on BP.
In addition, contrary to some other studies [43], daily
alcohol intake was not associated with BP in the present
investigation, which may be attributed to the relatively
low median intake level of our subjects, and/or, possibly,
due to the fact that our analysis was not stratified by
type of alcoholic beverages, patterns of drinking or
acute vs. chronic effects.
Our study has some limitations, including the cross-
sectional design, which limits our ability to establish
causal relationships. Due to the small sample size, it is
possible that some associations were classified as not
statistically significant because of a type II error. Partici-
pants in this study were volunteers, had a higher educa-
tional level and were more aware of health issues than
their peers in the general German population [26].
Further limitations are the use of self-reported data, the
indirect estimates of sun exposure and physical activity
and missing data on type and the exact dosage and
duration of vitamin D supplements as well as antihyper-
t e n s i v ed r u g s .W eh a v en oi n f o r m a t i o no ns e r u mc a l -
cium levels, which were linked to BP [40]. However,
other studies have shown, that the association between
25(OH)D and BP may be independent of serum calcium
[9].
Conclusion
In conclusion, 25(OH)D3 may be a negative determinant
of BP in elderly men, especially in those not taking anti-
hypertensive medicine. On the basis of our results, it
can be supposed that this effect is independent of iPTH,
body composition and lifestyle factors. Furthermore,
iPTH may be an independent negative determinant of
DBP in subjects not taking antihypertensive medicine.
Our findings indicate that an increase in serum 25(OH)
D3 levels in elderly men, even without vitamin D defi-
ciency, might contribute to the prevention of
hypertension.
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